MR
Mark Ragosa (CHIEF FINANCIAL OFFICER) filed 6 Form 4 reports in the trailing twelve months (0 purchases, 6 sales), most often in Kiniksa Pharmaceuticals International, plc (KNSA). The largest single filing was $3.4M of KNSA (36,563 sh across 3 lots, as filed), executed Nov 2. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
6
0 buys · 6 sells
Median delay
–
measured on stock purchases
Volume, ttmiDollar value disclosed in the trailing twelve months
$8.1M
shares × price, as filed
Last traded
Nov 2
Filed Nov 3
Median ADV $60.8M across their filed names
Open performance→Volume by month
Buys $0
Sells $15.0M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
6 filings
Sector per market data · by filing · past 12 months
Most traded names
KNSARecent filings
KNSASALE
Kiniksa Pharmaceuticals International, plc
View filing →
$2.3M88,395 sh across 3 lots
Exec Apr 29 2025
Filed May 1 2025 · 5:30 PM ET KNSASALE Kiniksa Pharmaceuticals International, plc View filing → $368K
15,944 sh × $23.11
Exec Mar 20 2025
Filed Mar 24 2025 · 5:30 PM ET KNSASALE Kiniksa Pharmaceuticals International, plc View filing → $470K
20,343 sh across 2 lots
Exec Mar 17 2025
Filed Mar 19 2025 · 5:30 PM ET KNSASALE Kiniksa Pharmaceuticals International, plc View filing → $809K
36,372 sh × $22.25
Exec Mar 12 2025
Filed Mar 14 2025 · 5:30 PM ET KNSASALE Kiniksa Pharmaceuticals International, plc View filing → $594K
27,829 sh across 2 lots
Exec Dec 6 2024
Filed Dec 10 2024 · 5:30 PM ET KNSASALE Kiniksa Pharmaceuticals International, plc View filing → $299K
13,993 sh across 2 lots
Exec Dec 3 2024
Filed Dec 5 2024 · 5:30 PM ET